Loss of HBsAg in Patients with High Levels of HBV-DNA During Treatment with Nucleoside or Nucleotide Analogs

Tadeusz W Lapinski 1, *, Monika Pazgan-Simon 2, Robert Plesniak 3 and Barbara Sobala-Szczygiel 4

1 Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland
2 Department of Infectious Disease and Hepatology, Wrocław Medical University, Wrocław, Poland
3 Clinical Department of Infectious Diseases, Faculty of Medicine, University Rzeszów, Rzeszów, Poland
4 Department and Clinic of Infectious Diseases and Hepatology, Medical University of Silesia, Katowice, Poland

*Corresponding author: Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland. Email: twlapinski@wp.pl

Abstract

Background: HBsAg is synthesized in the endoplasmic reticulum and is necessary for the formation of complete HBV particles. A decreased synthesis of this antigen leads to an intracellular inhibition of virus production.

Methods: The study aimed to assess the incidence of HBsAg elimination among 1,290 patients who suffered from chronic HBV infection undergoing an antiviral treatment with nucleoside or nucleotide analogs (NAs). Furthermore, possible predictive factors for this elimination were analyzed.

Results: A permanent HBsAg loss was confirmed in 3% of the patients, which was more frequent in men than in women (4.4% vs. 1.9%; P = 0.009). The HBsAg elimination occurred in 5% of HBeAg (+) patients and 2.8% of HBeAg (-) patients. The age of patients whose HBsAg was eliminated was higher than the age of the remaining patients (60 vs. 51 y/o). The effect of initially used pegylated interferon alfa (PEG-IFN) therapy on the HBsAg elimination was not observed. It occurred with the use of entecavir (ETV) and tenofovir (TDF); however, among patients treated with ETV, HBsAg was significantly more often eliminated in HBeAg (+) patients.

Conclusions: The HBsAg elimination in patients undergoing antiviral treatment occurs more often in men, patients with positive HBeAg before treatment, individuals above 60 years, and patients treated with ETV.

Keywords: HBV Elimination, Loss of HBsAg, Nucleoside/Nucleotide Analogues

1. Background

The HBV prevalence in Europe ranges from 1 to 7% (1). Infection with this virus may lead to liver cirrhosis and hepatocellular carcinoma (HCC). In HBV-infected patients, there is an integration of changed viral DNA with human deoxycholic acid of the host that may stimulate both the development of primary neoplastic cells and the inhibition of apoptotic processes that favor this process.

As known, 90% of HCC cases are diagnosed in patients with HBV, HCV, liver cirrhosis, and fatty liver. The development of this tumor is associated with genetic and epigenetic predispositions, activation of cell oncogenes, and inactivation of tumor suppressor genes. Chronic HBV infection decreases the quality of life and constitutes a real life-threat.

The viral pre-S1 protein contains hepatocyte binding sites and plays a key role in the synthesis of HBsAg and subsequent virion assembly. HBsAg is synthesized in the endoplasmic reticulum and the Golgi apparatus. In the cytoplasm, it connects with the HBV genome and creates a complete viral particle. A decreased HBsAg synthesis leads to the intracellular inhibition of virus production.

2. Objectives

The study aimed to assess the frequency of HBsAg elimination among patients suffering from chronic HBV infection undergoing antiviral treatment with nucleoside or nucleotide analogs (NUCs). Possible predictive factors of this elimination were analyzed, such as the duration of HBV infection, sex, age, HBeAg status, initial viremia, and the type of antiviral therapy after which the HBsAg elimination occurred.

3. Methods

The study included 1,290 patients (720 women and 570 men) with a mean age of 60 (18 - 84 y/o) that were undergo-
ing antiviral treatment due to chronic hepatitis B (Table 1). The patients were observed from 2014 to 2019.

Patients qualified for treatment were those chronically infected with HBV who had a minimum infection duration of six months (usually much longer). Patients eligible for treatment had HBeAg (+) minimum viral load of 20,000 IU/mL and anti-HBe (+) minimum viral load of 2,000 IU/mL. Liver biopsy or FibroScan was performed on treated patients to assess liver fibrosis. Based on the results, 90% of the patients showed slight fibrosis from 1 to 3 on a METAVIR or Scheuer scale. None of the patients had significantly elevated ALT levels (Table 1).

Before treatment, the patients were assessed for HBV viremia, HBsAg presence, HBeAg, ALT activity, AFP concentration, and the level of liver fibrosis. In all patients, the following was assessed every six months: HBV-DNA concentration, AFP, and the presence of HBsAg and HBeAg among patients with this antigen. In the case of HBeAg or HBsAg loss, the detection of anti-HBe or anti-HBs was determined every three months.

Statistical analysis was performed using the chi-square test \( (\chi^2) \) and the Mann-Whitney U-test. The statistical significance level was set at \( P < 0.05 \).

All patients gave their consent to participate in the study and receive therapy. All patients (from all Research Centers) were qualified for the treatment and treated according to the recommendations of the National Health Fund (therapeutic program B18.1). All patients signed informed consent forms to use their laboratory results in scientific research.

4. Results

All patients, regardless of HBeAg presence in serum, had HBV viremia \( \geq 4 \log_{10} \text{IU/mL} \). The permanent HBsAg loss within a 24-week observation period was confirmed in 39 (3%) individuals. The HBsAg loss occurred more often in men than in women (4.4% vs. 1.9%; \( P = 0.009 \)). The HBsAg loss was found in eight (5.0%) patients that were HBeAg (+) and 31 (2.8%) patients that were HBeAg (-). However, the difference was not statistically significant (Table 1).

The mean age of the patients who had eliminated HBsAg was 60 (28 - 82 y/o). Only were four patients younger than 45 y/o. The age of the patients who had eliminated HBsAg was greater than the age of other patients (60 vs. 51 y/o); however, no statistically significant difference was confirmed.

The elimination of HBsAg was much more frequent among patients with cirrhosis of the liver than in all patients (13/39 (33.3%) vs. 77/1290 (5.9%), chi-square test \( (\chi^2) = 44.8, P < 0.0001 \)).

Among all HBeAg (+) patients, an initial antiviral PEG-IFN therapy was commenced in 46 (29%) individuals, whereas it was the case of 396 (35%) patients in the group without HBeAg. In both groups, the treatment continued for 12 months. There was no influence of PEG-IFN on the HBsAg elimination right after the treatment and in the subsequent years.

In the group of patients with HBsAg elimination, the mean HBV viremia of HBeAg (-) individuals amounted to \( 7 \log_{10} \text{IU/mL} \), while in the group of HBeAg (+) patients, it was \( 8 \log_{10} \text{IU/mL} \). All patients from the latter group had viremia exceeding \( 7 \log_{10} \text{IU/mL} \) (Table 2).

The average infection duration among HBeAg (+) patients was 8.3 years (from 1 to 30 years), while among HBeAg (-) patients, it was 13.7 years (from 2 to 31 years). No relationship was confirmed between the infection duration and HBsAg elimination.

Of 39 patients with HBsAg elimination, 16 were treated with only one antiviral drug, 22 were treated initially with LMV and then with ETV or TDF, and one patient was initially on PEG-IFN and then on TDF. In both groups, the treatment continued for 12 months. There was no influence of PEG-IFN on the HBsAg elimination right after the treatment and in the subsequent years.

In patients treated with ETV, HBsAg was significantly more often eliminated in HBeAg (+) patients (Table 2). In five out of 39 (13%) patients in whom HBsAg was eliminated during the observation period, a liver transplant was performed due to liver failure secondary to liver cirrhosis (Table 2).

5. Discussion

The efficacy of various antiviral therapies varies among CHB patients, indicating that both viral and host factors can affect the results. Stelma et al. (2) treated 98 patients with CHB for 48 weeks with PEG-IFN and ADV. Five years after the treatment came to an end, the HBsAg elimination was confirmed in 19% of the patients with HBeAg and 16% of the patients without this antigen (2). Already in this study,
Table 1. Patients’ Profile (N = 1,290)$^a$

| Profile                                      | Positive HBeAg (N = 160; 12%) | Negative HBeAg (N = 1,130; 88%) |
|----------------------------------------------|-------------------------------|----------------------------------|
| Age in years, average (range)               | 18 - 84                       | 18 - 81                          |
| Women, %                                     | 85 (53)                       | 635 (56)                         |
| Men, %                                       | 75 (47)                       | 495 (44)                         |
| Last drug used                               |                               |                                  |
| Entecavir, No. (%)                           | 62 (39)                       | 441 (39)                         |
| Age in years, average (range)               | 47 (19 - 88)                  | 45 (19 - 77)                     |
| Viral load IU/mL, x (SD)                    | $3.8 \log^8 (1.0 \log^9)$    | $1.4 \log^8 (4.6 \log^9)$       |
| ALT IU/mL, x (SD)                           | 126 (70)                      | 114 (75)                         |
| AFP ng/mL, x (SD)                           | 5.5 (2.6)                     | 5.2 (2.6)                        |
| Average duration of infection, months (range)| 74 (24 - 180)                | 88 (24 - 240)                    |
| Average duration of treatment, months (range)| 72 (24 - 140)                | 84 (24 - 120)                    |
| Liver fibrosis from 1 - 3, No. (%)$^a$      | 56 (90.3)                     | 424 (96.2)                       |
| Cirrhosis, No. (%)                           | 6 (9.7)                       | 17 (1.8)                         |
| Tenofovir, No. (%)                           | 58 (36)                       | 368 (33)                         |
| Age in years, average (range)               | 44 (21 - 78)                  | 46 (19 - 77)                     |
| Viral load IU/mL, x (SD)                    | $2.9 \log^8 (9.2 \log^9)$    | $2.2 \log^8 (3.6 \log^9)$       |
| ALT IU/mL, x (SD)                           | 52 (38)                       | 58 (37)                          |
| AFP ng/mL, x (SD)                           | 6.6 (3.8)                     | 6.3 (7.3)                        |
| Average duration of infection, months (range)| 74 (24 - 140)                | 69 (24 - 105)                    |
| Average duration of treatment, months (range)| 95 (44 - 110)                | 85 (38 - 140)                    |
| Liver fibrosis from 1 - 3, No. (%)$^a$      | 49 (84.5)                     | 347 (94.3)                       |
| Cirrhosis, No. (%)                           | 9 (15.5)                      | 21 (5.7)                         |
| Lamivudine, No. (%)                          | 28 (17)                       | 115 (10)                         |
| Age in years, average (range)               | 46 (19 - 77)                  | 45 (18 - 77)                     |
| Viral load IU/mL, x (SD)                    | $2.9 \log^8 (9.0 \log^9)$    | $8.3 \log^8 (5.7 \log^9)$       |
| ALT IU/mL, x (SD)                           | 126 (71)                      | 115 (76)                         |
| AFP ng/mL, x (SD)                           | 5.6 (2.8)                     | 5.8 (5.6)                        |
| Average duration of infection, months (range)| 71 (24 - 180)                | 85 (24 - 200)                    |
| Average duration of treatment, months (range)| 107 (42 - 227)               | 127 (44 - 216)                   |
| Liver fibrosis from 1 - 3, No. (%)$^a$      | 26 (93)                       | 108 (94)                         |
| Cirrhosis, No. (%)                           | 2 (7)                         | 7 (6)                            |
| Other, No. (%)                               | 12 (8)                        | 206 (18)                         |
| Age in years, average (range)               | 45 (20 - 80)                  | 45 (21 - 77)                     |
| Viral load IU/mL, x (SD)                    | $3.2 \log^8 (8.9 \log^9)$    | $3.9 \log^8 (11 \log^9)$        |
| ALT IU/mL, x (SD)                           | 97 (46)                       | 109 (45)                         |
| AFP ng/mL, x (SD)                           | 6.1 (2.3)                     | 5.6 (2.7)                        |
| Average duration of infection, months (range)| 78 (44 - 118)                | 67 (42 - 115)                    |
| Average duration of treatment, months (range)| 108 (36 - 182)               | 116 (24 - 180)                   |
| Liver fibrosis from 1 - 3, No. (%)$^a$      | 10 (83.3)                     | 194 (94.2)                       |
| Cirrhosis, No. (%)                           | 2 (16.7)                      | 12 (5.8)                         |

$^a$Liver biopsy or FibroScan (rating scale: Scheuer or METAVIR).

$^b$Interrupted therapy, treatment with pegylated interferon alfa, LMV, ETV/TDV, and ADV.
Table 2. Frequency of HBsAg Elimination Concerning the Drug Used (%)

| Treatment Regimen                        | All Patients | HBsAg Elimination, No. (%) | HBsAg (-) | HBsAg (+) | Initial Viral Load, x (SD) | Duration of Treatment Until HBsAg Elimination, mo | Number of Patients Being Treated | HBsAg Elimination | Initial Viral Load, x (SD) | Duration of Treatment Until HBsAg Elimination, mo | Number of Patients Being Treated | HBsAg Elimination |
|-----------------------------------------|--------------|----------------------------|-----------|-----------|---------------------------|-----------------------------------------------|---------------------------------|---------------------|---------------------------|-----------------------------------------------|---------------------------------|---------------------|
| Total                                   | 1,290        | 39 (3.0)                   | 3.8 Log^7^ E/mL (9.1 Log^7^ E/mL) | 40         | 1,130                     | 31 (2.8)                                       | 3 (6.3)                         | 5 (5.0)              | 3.8 Log^7^ E/mL (1.4 Log^8^ E/mL) | 38                              | 360                              | 5 (5.0)              |
| Only ETV                                | 64           | 7 (7.4)                    | 3.1 Log^8^ E/mL (2.1 Log^8^ E/mL) | 48         | 73                        | 3 (4.1)                                       | 3 (5.0)                         |                     | 3.6 Log^8^ E/mL (4.9 Log^8^ E/mL) | 50                              | 21                               | 3 (5.0)              |
| Sequential therapy LMV followed by ETV  | 409          | 6 (3.5)                    | 3.1 Log^7^ E/mL (5.3 Log^7^ E/mL) | 76         | 360                       | 12 (3.8)                                      | 5 (3.0)                         |                     | 3.9 Log^7^ E/mL (4.8 Log^8^ E/mL) | 54                              | 41                               | 3 (3.8)              |
| Only ETV and LMV/ATV                    | 503          | 22 (4.4)                   | 6.6 Log^7^ E/mL (14.9 Log^7^ E/mL) | 62         | 416                       | 15 (3.4)                                      | 5 (5.0)^b                      |                     | 8.5 Log^7^ E/mL (1.5 Log^8^ E/mL) | 52                              | 82                               | 7 (5.0)^b             |
| Only TDF                                | 105          | 5 (4.3)                    | 1.0 Log^8^ E/mL (9.0 Log^8^ E/mL) | 47         | 88                        | 5 (5.3)^b                                      | 5 (5.0)                         |                     |                        | -                              | -                                | 27 (2.6)             |
| Sequential therapy LMV followed by TDF  | 33           | 0 (0.0)                    | 1.3 Log^7^ E/mL (9.3 Log^7^ E/mL) | 40         | 260                       | 5 (5.0)^b                                      | 4 (4.0)                         |                     |                        | 2.2 Log^6^ E/mL (2.4 Log^6^ E/mL) | 24                              | 31                               | 1 (0.3)              |
| Only TDF and LMV/TDF                    | 426          | 11 (2.6)                   | 6.9 Log^7^ E/mL (14.6 Log^7^ E/mL) | 41         | 360                       | 16 (3.7)                                      | 2.2 Log^6^ E/mL (2.4 Log^6^ E/mL) | 24                              | 38                               | 1 (0.3)             |
| Only LMV                                | 143          | 4 (2.8)                    | 1.4 Log^8^ E/mL (4.6 Log^8^ E/mL) | 305        | 135                       | 4 (5.5)^2 (5.0)                                | 3.4 Log^6^ E/mL (1.1 Log^8^ E/mL) | -                              | 28                               | 0                                |                     |
| Other treatment^c                        | 218          | 2 (0.9)                    | 8.3 Log^7^ E/mL (1.5 Log^8^ E/mL) | 18         | 204                       | 2 (0.9)^7                                      | -                               | -                               | 12                               | 0                                |                     |

^a Patients with liver cirrhosis. ^b Chi-square 8.09, P = 0.004. ^c PEG-IFN, Lamivudini, Entecavir/Tenofovir, Adefovir. One patient (HBsAg (-)) treated with ADV; initial viral load 4.2 Log^5^ E/mL: elimination of HBsAg after 12 months of therapy. One patient (HBsAg (-)) treated with ETV/TDF; initial viral load 1.2 Log^6^ E/mL: HBsAg elimination after 24 months of therapy.

Similar to the authors’ study, a more frequent HBsAg elimination was observed in HBeAg (+) patients.

Aziz et al. (3) assessed 110 patients with CHB that were treated with TDF for 48 months and did not confirm the HBsAg elimination in a single one of them. On the other hand, Alawad et al. (4) observed HBsAg clearance within a five-year treatment period or five years after the treatment stopped in 34% of patients treated with PEG-IFN and 37% of patients treated with NAs. The observation indicated high NA efficacy. Usually, the therapy efficacy is worse with the use of these drugs than with PEG-IFN.

Inoue et al. (5) analyzed the frequency of HBsAg elimination among CHB-patients depending on the HBV genotype. During a 10-year long antiviral therapy, the HBsAg elimination was confirmed in 3.6% of patients with B genotype and 0.7% of patients infected with C genotype. It was not confirmed that any of the antiviral drugs (LMV, ETV, TDF, and ADV) led to higher efficacy of HBsAg elimination (5). In Poland, the most common HBV genotypes are A (67%) and D (20%) (6). In the authors’ study, the HBsAg elimination was confirmed more often among HBeAg (+) patients (5%) than in HBeAg (-) patients (2.8%), but it was not significantly different. Having analyzed all patients, in some of them, the PEG-IFN treatment preceded NAs therapy; however, it did not result in a more common HBsAg elimination. Only one patient among those who lost HBsAg was administered PEG-IFN before NAs.

Yan et al. (7) achieved a considerable decrease in or loss of HBsAg in patients with chronic HBV infections without HBeAg who were administered PEG-IFN for 48 weeks. However, a vast majority of patients treated with PEG-IFN had initial viremia \( \leq 1000 \) IU/mL (7). Both PEG-IFN and NAs therapies rarely cause HBsAg elimination among patients suffering from chronic HBV infections (8). Numerous adverse reactions of PEG-IFN are the reasons behind the ever-increasing omission of this drug in the treatment of patients with chronic HBV infections.

A question about predictive factors for HBsAg elimination is more and more often raised, especially in the case of NAs treatment. In the authors’ study, patients with viremia \( \leq 2,000 \) IU/mL were not qualified for treatment due to the criteria specified in domestic guidelines and drug program (9). In the authors’ study, patients treated with PEG-IFN usually had high viremia, which could explain the lack of efficacy of PEG-IFN therapy.

The mechanism of NAs antiviral effect is associated
with their suppressive activity towards the synthesis of the virus’s DNA. However, in vitro studies have shown that ETV inhibits the priming of DNA-HBV polymerase, which presents an additional mechanism for the antiviral effects of this drug (10). Perhaps it is significant concerning a slightly more frequent HBsAg elimination during the ETV therapy observed in the authors’ study. A significantly more frequent HBsAg elimination in HBeAg (+) patients than in HBeAg (−) patients treated with ETV is interesting.

5.1. Conclusions

The HBsAg elimination in patients undergoing antiviral treatment is more common in men, patients with detectable HBeAg antigen, and individuals above 60 y/o. The liver cirrhosis was often diagnosed in patients who had HBsAg elimination. It appears that ETV is the best choice for patients with detectable HBeAg.

Footnotes

Authors’ Contribution: Study Design: Tadeusz W Lapinsk. Data Collection: Tadeusz W Lapinsk, Monika Pazgan-Simon, Robert Plesniak, and Barbara Sobala-Szczygiel. Statistical Analysis: Tadeusz W Lapinsk. Data Interpretation: Tadeusz W Lapinsk, Monika Pazgan-Simon, Robert Plesniak, and Barbara Sobala-Szczygiel. Manuscript Preparation: Tadeusz W Lapinsk, Monika Pazgan-Simon, Robert Plesniak, and Barbara Sobala-Szczygiel.

Conflict of Interests: The authors have no disclosure.

Ethical Approval: All patients (from all Research Centers) were qualified to the treatment and treated according to the recommendations of National Health Fund (therapeutic program B18.1).

Funding/Support: Own financing only by the authors.

Informed Consent: All patients gave their consent to participate in the study and receive therapy. All patients signed the informed consent forms to use their laboratory results in scientific research.

References

1. Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int. 2009;29 Suppl 1:133–9. doi: 10.1111/j.1478-3231.2008.01933.x. [PubMed: 19207977].
2. Stelma F, van der Ree MH, Jansen L, Peters MW, Janssen HLA, Zaatjier HL, et al. HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. J Viral Hepat. 2017;24(12):1107–13. doi: 10.1111/jvh.12738. [PubMed: 28532898].
3. Aziz M, Aziz H, Waheed Y, Gill ML. Predictors of Therapeutic Outcome to Nucleotide Reverse Transcriptase Inhibitor in Hepatitis B Patients. Viral Immunol. 2018;31(9):632–8. doi: 10.1089/vim.2018.0022. [PubMed: 30285571].
4. Alawad AS, Auh S, Suarez D, Ghany MG. Durability of Spontaneous and Treatment-Related Loss of Hepatitis B s Antigen. J Viral Hepat. 2017;24(12):1107–13. doi: 10.1111/jvh.12738. [PubMed: 28532898].
5. Inoue J, Akahane T, Nakayama H, Kimura O, Kobayashi T, Kisoa N, et al. Comparison of hepatitis B virus genotypes B and C among chronically hepatitis B virus-infected patients who received nucleos(t)ide analogs: A multicenter retrospective study. Hepatol Res. 2019;49(1):1263–74. doi: 10.1111/hepr.13398. [PubMed: 31254482].
6. Swiderska M, Pawlowska M, Mazur W, Tomaszewicz K, Simon K, Piekar ska A, et al. Distribution of HBV genotypes in Poland. Clin Exp Hepatol. 2015;5(1):2–4. doi: 10.5114/ceh.2015.51372. [PubMed: 28856248]. [PubMed Central: PMC452165].
7. Yan L, Zhu C, Li J, Chen L, Ding Y, Cao Z, et al. Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients. Infect Drug Resist. 2018;11:2001–9. doi: 10.2147/IDR.S15707. [PubMed: 30464542]. [PubMed Central: PMC520110].
8. Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, et al. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol. 2018;6(1):25–34. doi: 10.4121/JCTH.2017.00072. [PubMed: 29577029]. [PubMed Central: PMC5862996].
9. Polish Group of Experts for HBV, Flisiak R, Halota W, Jaroszewicz J, Juszczuk J, Malkowski P, et al. Recommendations for the treatment of hepatitis B in 2017. Clin Exp Hepatol. 2017;7(2):35–46. doi: 10.5104/ceh.2017.67626. [PubMed: 28956289]. [PubMed Central: PMC5497479].
10. Fung J, Lai CL, Seto WK, Yuen MF. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. J Antimicrob Chemother. 2011;66(12):2715–25. doi: 10.1093/jac/dkr388. [PubMed: 21965435].